Tyrosine kinase inhibitors (TKI) have significant off-target multi-kinase inhibitory effects.
Introduction
The tyrosine kinase inhibitors (TKIs) imatinib, nilotinib and dasatinib are remarkably effective as single-agent therapy for chronic myeloid leukemia (CML) in chronic phase (CP). [1] [2] [3] To date very few in vivo human studies have addressed the long-term impact of these molecular-targeted drugs on the immune function. Data from in vitro and animal studies have documented seemingly contradictory effects of imatinib on the immune response, ranging from impaired antigen-specific T-cell responses [4] [5] [6] to reversal of T-cell tolerance 7 and potentiation of anti-tumor immune responses. 8;9 The limited in vitro data available with second-generation TKIs nilotinib (Novartis) and dasatinib (Bristol-Myers Squibb) show impaired antigen-specific T-cell responses; [10] [11] [12] [13] [14] [15] however recent studies report rapid mobilization and expansion of BCR-ABL-negative lymphoid cells in dasatinib-treated patients. [16] [17] [18] Few studies have examined the impact of TKIs on B cell responses to antigen in vivo, 19 although hypogammaglobulinemia has been reported in CML patients treated with imatinib. 20 A recent murine study reported that imatinib may directly impair class-switch recombination following B cell activation through downregulation of activation-induced cytidine deaminase . 21 To date, no studies have examined the impact of first and secondgeneration TKIs on B cell responses to vaccination in patients with CML.
We hypothesized that TKI may interfere with vaccine-induced cellular and humoral immune responses in CML patients on TKI through their off-target multi-kinase inhibitory effects. 11;22;23 We characterized T and B cell responses to vaccination against influenza and pneumococcus in CP-CML patients receiving imatinib, dasatinib and nilotinib and healthy controls. We found that the B cell response to pneumococcal vaccine is significantly impaired in CML patients, associated with loss of memory B cell subsets. Furthermore, we showed that all 3 TKIs suppress an important kinase in B cell receptor signaling (BCR) and survival, 
Design and methods

Patients and controls
Fifty-one CP-CML patients in complete cytogenetic response (CCyR) on standard-dose imatinib (n=26), dasatinib (n=13) or nilotinib (n=12) and 24 adult controls were recruited in this study during two influenza seasons (2008 and 2009) . Patient characteristics are summarized in Table- 1. All patients were on second-line therapy with dasatinib or nilotinib and had failed previous therapy with imatinib (supplementary Table 1 ). Healthy controls were recruited amongst hospital staff. The median age for CML patients was 52 years and for controls 41 years (p=0.10). All patients and controls were vaccinated against influenza Peripheral blood mononuclear cells (PBMCs) and serum samples were collected from all patients and donors prior to vaccination and responses were assessed at 4 weeks and at 2-3 months post-immunization. All patients and adult controls gave informed written consent and the local institutional ethics board approved the study protocol.
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Determination of influenza specific CD8+ and CD4+ T-cell responses by flow cytometry
Multi-parameter flow-cytometry was employed to assess immunological T-cell responses to influenza virus both quantitatively by GILGFVFTL/HLA-201 (FluMP) pentamer staining, and qualitatively using intracellular cytokine (IC) assay for TNF-α, IFN-γ, IL-2 and the cytotoxicity marker CD107a as described previously.
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Cells were acquired on FACS Calibur TM (BD Biosciences, Oxford UK) and data were analyzed using FlowJoTM software (TreeStar, San Carlos, CA).
Determination of pneumoccocal serum titers for IgM and IgG
Serum titers of pneumococcal IgM and IgG antibodies were determined using ELISA as previously described.
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Determination of plasma levels of imatinib, dasatinib and nilotinib TKI and metabolite plasma detection was based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) using TurboFlow sample preparation as previously described. 
Intracellular phospho-specific flow cytometric assay
We assessed the impact of therapeutic doses of imatinib, dasatinib and nilotinib on Btk phosphorylation using intracellular phosphor-specific flow cytometric assay, following co- 
Results
Vaccination with influenza A induces CD8+ and CD4+ T-cell responses in patients on
TKI and healthy controls
The induction of T-cell responses to Flu vaccination was assessed directly ex-vivo by flowcytometric enumeration of antigen-specific CD8+ and CD4+ T-lymphocytes using IC assay for IFN-γ and TNF-α. A T-cell response was defined to be Flu-specific if at least one cytokine 
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We next evaluated the functional quality of the influenza vaccine-induced T-cell response by flow-cytometric analysis of markers related to T-helper cell-1 (TNF-α, IFN-γ and IL-2) and degranulation/cytotoxicity (CD107a) in individuals with a positive vaccine-induced T cell response (responders) and in whom sufficient numbers of cells were available for analysis, i.e. 9/24 'responders' in the CML and 7/15 'responders' in the healthy control groups. We found no significant differences in the quality of the T-cell response to influenza vaccine in the two groups as summarized in Supplementary Table 2C .
CML patients on TKI achieve lower pneumococcal IgM titers after vaccination
Forty five CML patients on TKI and 12 healthy controls were vaccinated against the polysaccharide pneumococcal (PPS) vaccine (Pneumovax II) and all could be evaluated for response. Prior to vaccination, the median pneumococcal IgG levels were 123 U/ml in CML patients compared to 71.5 U/ml in controls (p=0.3); 16/45 patients and 3/12 controls had prevaccination pneumococcal IgG levels >200 U/ml (p=0.7). In contrast, the pre-vaccine pneumococcal IgM levels were significantly lower in CML patients on TKI (median 15, range 3-72 U/ml) compared to healthy controls (median 38, range 13-78 U/ml), p=0.002. We also assessed humoral responses to the vaccine in patients and controls without prior evidence of pneumococcal infection or immunization (defined as IgG <200 U/ml prior to vaccination). Of 24/45 evaluable patients, 6/24 (25%) failed to mount both an IgM and IgG response compared to 0/9 healthy controls (p=0.15), suggesting the presence of global B cell memory impairment in a proportion of CML patient on TKI. The characteristics of the 6 CML patients who failed to mount an IgM and IgG response to PPS vaccine are presented in Table- 1B. We found no significant differences in the underlying characteristics (including age, Sokal score, spleen size, duration and response to TKI therapy) between the 6/24 patients who failed to mount a humoral response compared to the 18/24 responders.
We did not find significant differences in the post-vaccine humoral response rates ( Table-1B) .
Treatment with imatinib is associated with a significant decrease in the frequencies of IgM memory and class switched memory B cells
To investigate whether the loss of IgM memory B cell subset in CML patients is related to CML itself or to treatment with TKIs, we studied B cell subsets in paired samples collected from 15 CP-CML patients at diagnosis and once CCyR was achieved on imatinib. The patient characteristics are summarized in Table- FACS plots from two representative patients are presented in Figure-3F .
Plasma from CML patients on TKI co-incubated with autologous B cells inhibits Btk phosphorylation
To understand the molecular basis through which TKIs inhibit B cell activation, we co- Table-3) .
We noted significant inhibition in the mean fluorescence intensity (MFI) and percentage Btk phosphorylation in B cells of patients treated with imatinib (median inhibition 50%, range 35-53%), nilotinib (median inhibition 65%, range 61-68%) and dasatinib (median inhibition 83%, range 81-86%), (Figure-4) .
Imatinib, dasatinib and nilotinib inhibit Btk and PLC-γ2 phosphorylation in a dosedependent manner
We also assessed the impact of increasing doses of imatinib, dasatinib and nilotinib on the 
Discussion
In this study we show that CP-CML patients treated with imatinib, dasatinib or nilotinib have We found a strong correlation between pneumococcal IgM vaccine response and IgM memory B cell frequencies; 60% of patients with CP-CML on TKI had significantly impaired Conversely, Ph+ B cells may be hypo-or dysfunctional and as a result fail to mount an effective humoral response to a pathogenic antigen. However, our data do not support these scenarios as we observed a significant decrease in the frequencies of memory B cell subsets at CCyR, when a state of minimal residual disease was achieved, compared to diagnosis.
Instead, our results favor a direct quantitative and qualitative effect of TKI on B cells. We found a significant reduction in IgM memory and switched memory B cells following treatment with imatinib, suggesting that TKIs might interfere with the production and maintenance of B cell memory. These data may provide a possible explanation for recent reports of graft-versus-host disease (GVHD) response to imatinib, despite a lack of we showed that all 3 TKI suppress Btk activity in memory B cell subsets, known to be critical to B cell memory development and class switching. 48 Our study was not designed to address the underlying reasons for differential responses to pneumococcal vaccine in CML patients on TKI. A possible explanation could be variations in serum TKI levels due to inter-individual differences in drug metabolism 49 or adherence that may in turn impact the in vivo B cell response to the vaccine. 50 For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Pneumococcal IgM at 4 weeks (U/ml)
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